Skip to Main Content

Author Details

Alice A Gibson
The Ohio State University
1997
40
24
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37347545Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy.JCI Insight2023
35955741MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia.Int J Mol Sci2022
35383108Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake.Mol Pharmacol2022
36506732Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity.Cancer Res Commun2022
36145680A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug-Drug Interaction Liabilities.Pharmaceutics2022
32905646DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.Clin Transl Sci2021
33495337Targeting OCT3 attenuates doxorubicin-induced cardiac injury.Proc Natl Acad Sci U S A2021
33790797Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1.Front Pharmacol2021
33664059Regulation of OATP1B1 Function by Tyrosine Kinase-mediated Phosphorylation.Clin Cancer Res2021
34959286<i>In Vitro</i> and <i>In Vivo</i> Inhibition of MATE1 by Tyrosine Kinase Inhibitors.Pharmaceutics2021
34518298Gilteritinib Inhibits Glutamine Uptake and Utilization in <i>FLT3</i>-ITD-Positive AML.Mol Cancer Ther2021
32484793Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice.J Clin Invest2020
32825359Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib.Pharmaceutics2020
32989230Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.Br J Cancer2020
32114507Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions.Drug Metab Dispos2020
29337310OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.J Clin Invest2018
28689374Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity.Clin Transl Sci2017
28371445Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.Clin Transl Sci2017
28209616OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.Cancer Res2017
26842729ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression.Clin Transl Sci2016
26677977Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.Cancer Res2016
26663398Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia.Clin Pharmacol Ther2016
27537383Loss of SLCO1B3 drives taxane resistance in prostate cancer.Br J Cancer2016
26979622A phosphotyrosine switch regulates organic cation transporters.Nat Commun2016
25952649Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.Cancer Res2015
25848011Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions.Proc Natl Acad Sci U S A2015
24916697Cisplatin-induced renal injury is independently mediated by OCT2 and p53.Clin Cancer Res2014
24755470Influence of drug formulation on OATP1B-mediated transport of paclitaxel.Cancer Res2014
23340295Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.Clin Cancer Res2013
23863876Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance.Clin Pharmacol Ther2013
23776246Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.Proc Natl Acad Sci U S A2013
23794731Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.Clin Cancer Res2013
23757163Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics.Mol Cancer Ther2013
22927483Ontogeny and sorafenib metabolism.Clin Cancer Res2012
22990751OATP1B1 polymorphism as a determinant of erythromycin disposition.Clin Pharmacol Ther2012
22711709Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.Clin Cancer Res2012
21451505Effect of ABCC2 (MRP2) transport function on erythromycin metabolism.Clin Pharmacol Ther2011
9516963Selective sensitization to DNA-damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type p53 overexpression.Clin Cancer Res1998
10200495Expression of genes that regulate Fas signalling and Fas-mediated apoptosis in colon carcinoma cells.Cell Death Differ1998
9815616The fas signaling pathway is functional in colon carcinoma cells and induces apoptosis.Clin Cancer Res1997
  • 1 - 40 of 40

Recommended Authors

Xun Bao
Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute
Career Start Year 2014
Number of shared co-authors 1
Eugene C Chen
Department of Drug Metabolism and Pharmacokinetics, Inc.
Career Start Year 2010
Number of shared co-authors 2
Lawrence Lin
University of California San Francisco
Career Start Year 2009
Number of shared co-authors 1
Ahmed Aman
Ontario Institute for Cancer Research, University Avenue
Career Start Year 2007
Number of shared co-authors 0
John F Reilly
Goldfinch Bio Inc.
Career Start Year 2007
Number of shared co-authors 0
Ligong Chen
Tsinghua University
Career Start Year 2006
Number of shared co-authors 1
Kari M Morrissey
Amunix Pharmaceuticals
Career Start Year 2006
Number of shared co-authors 1
Jordi Rodon
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 2
P??r Matsson
University of Gothenburg
Career Start Year 2005
Number of shared co-authors 2
Leslie W Chinn
Genentech Inc.
Career Start Year 2003
Number of shared co-authors 1
Sook Wah Yee
University of California San Francisco
Career Start Year 2001
Number of shared co-authors 4
Cristina Rodr??guez-Antona
Spanish National Cancer Research Center (CNIO)
Career Start Year 2000
Number of shared co-authors 1
Rose Hurren
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 0
Liewei Wang
Mayo Clinic
Career Start Year 1999
Number of shared co-authors 1
Mahadev Rao
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences
Career Start Year 1998
Number of shared co-authors 0
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 3
Christopher Calabrese
St. Jude Children's Research Hospital
Career Start Year 1997
Number of shared co-authors 3
David de Graaf
Syntimmune Inc.
Career Start Year 1995
Number of shared co-authors 0
Deanna L Kroetz
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 4
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 0
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 4
Francois Pognan
Novartis
Career Start Year 1988
Number of shared co-authors 0
Chiara Riganti
University of Turin
Career Start Year 1985
Number of shared co-authors 0
Mark J Ratain
University of Chicago
Career Start Year 1985
Number of shared co-authors 5
Howard L McLeod
Center for Precision Medicine and Functional Genomics, Utah Tech University
Career Start Year 1979
Number of shared co-authors 9
Kathleen M Giacomini
University of California San Francisco
Career Start Year 1978
Number of shared co-authors 6
Anne Monks
Institute of Biomedical Engineering (IBME), University of Oxford
Career Start Year 1976
Number of shared co-authors 0
Paul Workman
The Institute of Cancer Research
Career Start Year 1974
Number of shared co-authors 1
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 1
James H Doroshow
National Cancer Institute, National Institutes of Health
Career Start Year 1974
Number of shared co-authors 2

Collaborators

Alex Sparreboom
Ohio State University
Co-authored papers 35
Shuiying Hu
The Ohio State University
Co-authored papers 29
Sharyn D Baker
Ohio State University
Co-authored papers 21
Lie Li
Sino-French Hoffmann Institute, Guangzhou Medical University
Co-authored papers 13
Jason A Sprowl
School of Pharmacy and Pharmaceutical Sciences, University at Buffalo
Co-authored papers 11
Guoqing Du
Second Affiliated Hospital of Harbin Medical University
Co-authored papers 7
Navjotsingh Pabla
The Ohio State University
Co-authored papers 6
Giuliano Ciarimboli
University Hospital Munster
Co-authored papers 5
Guido Cavaletti
NeuroMI (Milan Center for Neuroscience)
Co-authored papers 5
Aksana Vasilyeva
St Jude Children's Research Hospital
Co-authored papers 5
Taosheng Chen
St. Jude Children's Research Hospital
Co-authored papers 5
Su Sien Ong
St. Jude Children's Research Hospital
Co-authored papers 4
Eberhard Schlatter
University Hospital Muenster
Co-authored papers 4
Stanley Pounds
St. Jude Children's Research Hospital.
Co-authored papers 3
Anne T Nies
and University of Tuebingen, University of Tuebingen
Co-authored papers 3
Daelynn R Buelow
The Ohio State University
Co-authored papers 3
Jan H M Schellens
Department of Pharmaceutical Sciences, Utrecht University
Co-authored papers 2
Matthias Schwab
and of Biochemistry and Pharmacy, University of Tuebingen
Co-authored papers 2
William E Evans
Departments of Oncology. St. Jude Children's Research Hospital
Co-authored papers 2
Ronald de Wit
Erasmus MC Cancer Institute
Co-authored papers 2
Andrej Sali (CM4AI)
University of California San Francisco
Co-authored papers 1
Lara E Sucheston-Campbell
The Ohio State University
Co-authored papers 1
Shashank Bharill
University of California berkeley
Co-authored papers 1
Robert B Diasio
Mayo Clinic
Co-authored papers 1
Rachel A Ness
4Department of Pharmacy, Memphis Veterans Affairs Medical Center
Co-authored papers 1
Ehud Y Isacoff
University of California berkeley
Co-authored papers 1
Martijn P Lolkema
Erasmus MC Cancer Institute
Co-authored papers 1
Charles L Loprinzi
Mayo Clinic
Co-authored papers 1
Wenwei Lin
St. Jude Children's Research Hospital
Co-authored papers 1
Adrian Stecula
Schools of Pharmacy and Medicine, University of California san francisco
Co-authored papers 1
Release 1.2